Results 1 to 10 of about 7,987 (192)
Apatinib for molecular targeted therapy in tumor [PDF]
Drug Design, Development and Therapy, 2015 As tumor angiogenesis is one of the hallmarks of cancer, the inhibition of vascular endothelial growth factor signaling has become an attractive anticancer approach. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2, has demonstrated encouraging anticancer activity across a broad range of malignancies, including ...
Haijun Zhang
exaly +7 more sources
Cellular Physiology and Biochemistry, 2017 Background/Aims: Anaplastic thyroid carcinoma (ATC) is one of the most lethal human malignancies, and there is no efficient method to slow its process. Apatinib, a novel tyrosine kinase inhibitor (TKI), has been confirmed for its efficacy and safety in ...
Zhijian Jin +7 more
doaj +3 more sources
Computational and Structural Biotechnology Journal, 2023 Apatinib is known to be a highly selective vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with anti-angiogenic and anti-tumor properties. In a phase III study, the objective response rate to apatinib was low.
Yosui Nojima +12 more
doaj +2 more sources
Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
Frontiers in Oncology, 2021 Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used off-label for the treatment of many other malignancies.
Xiaohui Niu
exaly +3 more sources
Apatinib inhibits synovial sarcoma progression and angiogenesis via VEGFR2-mediated AKT/FOXO3A and ERK1/2/FOXM1 signaling pathways [PDF]
Cell Death DiscoverySynovial sarcoma (SS) is a highly aggressive soft-tissue malignancy with limited therapeutic options for advanced disease. Here, we report that apatinib, a selective VEGFR2 tyrosine kinase inhibitor, exerts potent antitumor and anti-angiogenic activity ...
Ruijie Liu +8 more
doaj +2 more sources
Frontiers in Oncology, 2022 PurposeProgrammed cell death protein 1 (PD-1) inhibitor plus apatinib is reported to be a promising strategy for advanced cancers. Moreover, a PD-1 inhibitor or apatinib exerts a certain efficacy in advanced colorectal cancer (CRC), whereas their ...
Dengdeng Pan +7 more
doaj +1 more source
Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
Frontiers in Oncology, 2022 BackgroundBoth apatinib and programmed death 1 (PD-1) monoclonal antibody (mAb) monotherapy have been licensed in China for the third-line treatment of advanced gastric cancer (AGC).
Qingli Cui +6 more
doaj +1 more source
Frontiers in Oncology, 2022 BackgroundOsteosarcoma commonly develops during childhood and adolescence. Only one-third of osteosarcoma patients have been clinically detected over the age of 40 years, and the survivorship of those patients is quite dismal.
Taojun Gong +8 more
doaj +1 more source
Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma
Frontiers in Oncology, 2021 BackgroundPrimary retroperitoneal liposarcomas (RLPSs) are rare heterogeneous tumors for which there are few effective therapies. Certain anti-angiogenic tyrosine kinase inhibitors have demonstrated efficacy against various solid tumors. The aims of this
Lixuan Cui +11 more
doaj +1 more source
The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
Open Life Sciences, 2023 Chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains the first treatment choice. Angiogenesis inhibitors are effective for lung cancer treatment. This study explored whether chemotherapy combined with angiogenesis inhibitors could achieve
Zhou Ling +7 more
doaj +1 more source